Arrowhead Pharmaceuticals, Inc. ARWR
49.00 USD -0.24 (-0.49%)
At closeNov 11, 2026, 6:28 AM EST
50.10 +1.10 +2.24%
Pre-market · Nov 11, 6:28 AM ET
47.90 Day range 50.56
37.06 52-week range 95.49
- YTD
- -26.19%
- 1 year
- +22.96%
News
businesswire.com Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026…
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Reported Saturday, Arrowhead Presents Plozasiran Data At AHA 2026 Showing 78% Lower Acute Pancreatitis Event Rate Versus Placebo And Sustained Triglyceride Reductions, Plus ARO-DIMER-PA Lowering LDL Cholesterol And Triglycerides Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus…
gurufocus.com Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at
businesswire.com Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the…
benzinga.com Arrowhead Refinances Debt, Cuts Borrowing Costs And Boosts Financial Flexibility With New $400M Sixth Street Loan - Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount- New $400 million term loan priced at SOFR plus 5.50%- Debt has no scheduled…
businesswire.com Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing…
benzinga.com Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026 – Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking…
benzinga.com Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients…
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
benzinga.com HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
benzinga.com Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.- benzinga.com Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau…
- benzinga.com Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau…